The emergin role of clozapine in the treatment of movement disorders
Identifieur interne : 001F83 ( Main/Exploration ); précédent : 001F82; suivant : 001F84The emergin role of clozapine in the treatment of movement disorders
Auteurs : Stewart A. Factor ; Friedman [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 1997-07.
English descriptors
- KwdEn :
Abstract
Clozapine, the only commercially available atypical neuroleptic, is approved for the treatment of schizophrenic patients who are unresponsive to or intolerant of typical neuroleptics. It has an unusual pharmacologic profile compared with standard neuroleptics, and it follows that clinical response to this drug is also different. It has shattered the notion that a drug must be capable of inducing or worsening parkinsonism to be a potent antipsychotic. Based on these findings, it is being used increasingly by neurologists for psychiatric and nonpsychiatric problems in patients with movement disorders. The most common use for clozapine among neurologists is in the management of druginduced psychosis in Parkinson's disease (PD). This problem has been a source of increased morbidity and mortality in PD because of a lack of adequate therapeutic intervention. At this time, because of success in numerous open trials, with improvement of >80% of patients, clozapine therapy for psychosis in PD is becoming the standard of care. It also appears to be of value in the management of some motor features of PD, including tremors and dyskinesia and possibly even sensory symptoms such as akathisia and pain. The literature also suggests that clozapine may be of potential benefit in hyperkinetic movement disorders including essential tremor, Huntington's disease, and tardive dyskinesia. We review the current data concerning the use of clozapine in patients with these movement disorders and others.
Url:
DOI: 10.1002/mds.870120403
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The emergin role of clozapine in the treatment of movement disorders</title><author><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A." last="Factor">Stewart A. Factor</name></author><author><name sortKey="Friedman" sort="Friedman" uniqKey="Friedman" last="Friedman">Friedman</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:258A5F459AF3C8D1DAEEE8E0C710C25B60082FED</idno><date when="1997" year="1997">1997</date><idno type="doi">10.1002/mds.870120403</idno><idno type="url">https://api.istex.fr/document/258A5F459AF3C8D1DAEEE8E0C710C25B60082FED/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002790</idno><idno type="wicri:Area/Main/Curation">002445</idno><idno type="wicri:Area/Main/Exploration">001F83</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The emergin role of clozapine in the treatment of movement disorders</title><author><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A." last="Factor">Stewart A. Factor</name><affiliation><wicri:noCountry code="subField">New York;</wicri:noCountry></affiliation></author><author><name sortKey="Friedman" sort="Friedman" uniqKey="Friedman" last="Friedman">Friedman</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Memorial Hospital of Rhode Island, Pawtucket, Rhode Island</wicri:regionArea><placeName><region type="state">Rhode Island</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1997-07">1997-07</date><biblScope unit="volume">12</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="483">483</biblScope><biblScope unit="page" to="496">496</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">258A5F459AF3C8D1DAEEE8E0C710C25B60082FED</idno><idno type="DOI">10.1002/mds.870120403</idno><idno type="ArticleID">MDS870120403</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clozapine</term><term>Hyperkinetic movement disorders</term><term>Parkinson's disease</term><term>Psychosis and parkinsonism</term><term>Tardive dyskinesia</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Clozapine, the only commercially available atypical neuroleptic, is approved for the treatment of schizophrenic patients who are unresponsive to or intolerant of typical neuroleptics. It has an unusual pharmacologic profile compared with standard neuroleptics, and it follows that clinical response to this drug is also different. It has shattered the notion that a drug must be capable of inducing or worsening parkinsonism to be a potent antipsychotic. Based on these findings, it is being used increasingly by neurologists for psychiatric and nonpsychiatric problems in patients with movement disorders. The most common use for clozapine among neurologists is in the management of druginduced psychosis in Parkinson's disease (PD). This problem has been a source of increased morbidity and mortality in PD because of a lack of adequate therapeutic intervention. At this time, because of success in numerous open trials, with improvement of >80% of patients, clozapine therapy for psychosis in PD is becoming the standard of care. It also appears to be of value in the management of some motor features of PD, including tremors and dyskinesia and possibly even sensory symptoms such as akathisia and pain. The literature also suggests that clozapine may be of potential benefit in hyperkinetic movement disorders including essential tremor, Huntington's disease, and tardive dyskinesia. We review the current data concerning the use of clozapine in patients with these movement disorders and others.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Rhode Island</li></region></list><tree><noCountry><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A." last="Factor">Stewart A. Factor</name></noCountry><country name="États-Unis"><region name="Rhode Island"><name sortKey="Friedman" sort="Friedman" uniqKey="Friedman" last="Friedman">Friedman</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F83 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001F83 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:258A5F459AF3C8D1DAEEE8E0C710C25B60082FED
|texte= The emergin role of clozapine in the treatment of movement disorders
}}
| This area was generated with Dilib version V0.6.23. |  |